| Literature DB >> 32170553 |
Yasuaki Takeji1, Tomohiko Taniguchi2, Takeshi Morimoto3, Naritatsu Saito1, Kenji Ando2, Shinichi Shirai2, Yuichi Kawase4, Takeshi Kitai5, Hiroki Shiomi1, Eri Minamino-Muta1, Shintaro Matsuda1, Kazuhiro Yamazaki6, Makoto Miyake7, Koichiro Murata8, Norio Kanamori9, Chisato Izumi10, Hirokazu Mitsuoka11, Masashi Kato12, Yutaka Hirano13, Tsukasa Inada14, Kazuya Nagao14, Hiroshi Mabuchi15, Yasuyo Takeuchi16, Keiichiro Yamane17, Mamoru Toyofuku18, Mitsuru Ishii19, Moriaki Inoko20, Tomoyuki Ikeda21, Katsuhisa Ishii22, Kozo Hotta23, Toshikazu Jinnai24, Nobuya Higashitani24, Yoshihiro Kato25, Yasutaka Inuzuka26, Yuko Morikami27, Kenji Minatoya6, Takeshi Kimura28.
Abstract
Two randomized control trials demonstrated that transcatheter aortic valve implantation was associated with 1-2 year clinical outcomes comparable or even superior to surgical aortic valve replacement (SAVR) in low surgical risk patients with severe aortic stenosis (AS). However, no previous study has reported the clinical outcomes after SAVR in Japanese patients with low surgical risk. From 3815 consecutive patients enrolled in the CURRENT AS registry, we retrieved 220 patients who underwent SAVR in reference to the inclusion and exclusion criteria of the PARTNER 3 trial. Age and surgical risk score in the current study population were comparable to those in the PARTNER 3 trial (Age: 75 years versus 74 years, and STS-PROM score: 2.3 versus 1.9). The cumulative incidence of a composite all-cause death or stroke was comparable between the current study population and the SAVR patients in the PARTNER 3 trial both at 30-day (2.3% versus 3.3%), and at 1-year (4.1% versus 4.9%). The clinical outcomes of SAVR in low surgical risk patients with severe AS selected from a real world Japanese registry according to the inclusion and exclusion criteria of the PARTNER 3 trial was favorable and numerically comparable to those of SAVR patients in the PARTNER 3 trial.Entities:
Keywords: Aortic stenosis; Surgical aortic valve replacement
Mesh:
Year: 2020 PMID: 32170553 DOI: 10.1007/s12928-020-00658-2
Source DB: PubMed Journal: Cardiovasc Interv Ther ISSN: 1868-4297